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treatment response in Kawasaki disease
Michael A Portman1*, Howard W Wiener2, Miriam Silva1, Aditi Shendre2 and Sadeep Shrestha2*Abstract
Background: Genetic variants in the inhibiting FcγRIIB mediate anti-inflammatory responses and influence IVIG
refractoriness (IVIG-R). However, these variants are rare in Asian and Hispanic populations so other genes in the
pathway could be potentially involved. IVIG is ineffective in mice lacking SIGN-R1, a related molecule to human
DC-SIGN. Further, DC-SIGN is a known receptor for sialylated Fc, the component responsible for the anti-inflammatory
action of IVIG. Thus, we hypothesized that DC-SIGN would also be involved in the pathway of IVIG response in
Kawasaki Disease (KD) patients.
Findings: A case-control approach was performed to examine the differential distribution of five single nucleotide
polymorphisms (SNPs) in DC-SIGN promoter with IVIG-R among White (158 vs. 62), Asian (64 vs. 12) and Hispanic
(55 vs. 20) KD patients. Distinct differences in allele frequency distributions of several variants in the DC-SIGN
promoter were observed in the three ethnic groups. Further, Asians with the major allele “A” in rs2287886 were
more likely (OR = 1.76, p = 0.04) to be IVIG non-responder, but this allele is a minor allele in other two ethnic
groups, where the association was not apparent.
Conclusions: DC-SIGN can potentially complement the role of FcγRIIB in the anti-inflammatory cascade involved
in the IVIG response mechanism.
Keywords: Kawasaki disease, IVIG treatment response, FcγR, Coronary artery disease, DC-SIGNFindings
Kawasaki Disease is a diffuse self-limited vasculitis occur-
ring predominantly in children [1,2]. This disease can leave
permanent damage to the coronary arteries, characterized
by ectasia and/or aneurysm formation. Although often
classified as an autoimmune disease, the precise etiology
remains unknown. High dose intravenous immunoglobulin
(IVIG) is the principal treatment for acute KD [3-5]. IVIG
is often administered for the suppression of autoantibody-
triggered inflammation in a variety of clinical settings;
however, the mechanism of IVIG anti-inflammatory action
in KD, as well as in other autoimmune diseases, remains
elusive in humans. Elucidating the mechanisms of IVIG
action is particularly important for KD, as a significant
portion of patients do not respond appropriately, and are
termed IVIG refractory (IVIG-R) [6-8].* Correspondence: Michael.portman@seattlechildrens.org; sshrestha@uab.edu
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reproduction in any medium, provided the orIn mice, human IVIG action requires sialylation at a
single N-linked glycosylation site (amino acid 297) in the
Fc portion of lgG as well as expression of the inhibitory
Fcγ receptor 2B [9,10]. The sialylated IgG represents
only 10 to 20% of human IVIG and interacts with a lectin
receptor [9], specific intercellular adhesion molecule-3
grabbing nonintegrin homolog-related 1 (SIGN-R1), on
inflammatory cells [11]. Similar interaction occurs with
Dendritic Cell-Specific Intercellular adhesion molecule-3
Grabbing Nonintegrin (DC-SIGN), also known as CD209,
the human orthologue for this receptor. DC-SIGN recog-
nizes high-mannose glycans from a variety of pathogens,
and acts as a pattern recognition receptor bridging innate
and adaptive immunity. There has been some evidence
demonstrating the role of DC-SIGN promoter variants in
the susceptibility to or the protection against various
infectious diseases, such as dengue fever, tuberculosis,
and AIDS [12-14]. The IgG DC-SIGN interaction triggers
a cascade, which promotes an increase in macrophage
surface expression for FcγR2B [11]. This inhibitory
FcγR cross-links with activating FcγRs and modifiesl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in KD have implicated FcγR2B as an important component
in the IVIG response [16]. However, other factors, in par-
ticular DC-SIGN, which presumably appears downstream
from FcγR2B in the anti-inflammatory cascade [11], may
play an important role in IVIG treatment mechanism.
Previously, we have shown that the minor allele, A at
IIB-120 (T/a) in inhibiting FcγR2B influence IVIG-R
among whites, OR = 2.78 [1.02-7.69] [16]. Specifically,
none of the IVIG-R individuals were AA homozygote but
5/124 (4%) were homozygote among responders and also
the heterozygotes were more frequent (23% vs. 11%) among
the white responders. However, these variants are absent in
Asians and rare in Hispanic populations so other genes
in the pathway could be involved in the IVIG mechanism
in different populations.
Based on this hypothesis, we examined the influence
of five single nucleotide polymorphisms (SNPs) in the
promoter region of DC-SIGN that have been reported to
a) influence the promoter activity and b) are associated
with several infectious diseases [13,14,17-22], with IVIG
response among KD patients of three ethnic groups -
Whites, Asians and Hispanics. KD patients who were
treated with IVIG and had documented response data
from our ongoing cohort recruited from Seattle
Children’s Hospital, Oakland Children’s Hospital, and
Primary Children’s Hospital of Utah were included in this
study. The demographics of the patients and cohort have
been previously described in detail [15,16]. KD was diag-
nosed following the standard epidemiological criteriaTable 1 PCR and pyrosequencing primers used in the analysi
SNP
Variants†
First round nested PCR
rs# (5’-3’)
(Nucleotide position)*
rs2287886 G/a F: Biotin AGCTTTTATTTC
(-139) R: CTTGAAAGATCCGGCC
S: GCTCTGATGCTTTCCAC
rs4804803 A/g F ATGGTCTGGGGTTGAC
(-336) R Biotin GAGGACAGCAG
S CCTCCACTAGGGCAAG
rs735240 G/a F Biotin CAGTAAAAGGA
(-939) R CCTTCAAAGGTTAGTTC
S GCCTGTTCTCAAAATTC
rs11465360 C/a F Biotin CAAAGTAAAGA
(-1089) R GGGGTTTCTGTATGCTG
S GATGTGCATTTACCAC
rs4804804 G/a F AGAAACCAGCAGGAAC
(-1466) R Biotin GTCATGGCACTG
S CTGCCTCATTGCTCG
*Nucleotide position as described in Martin et al. [14]; † second variant in small lettrecommended by the American Heart Association and
American Academy of Pediatrics (AHA/AAP) [23]. A
standard treatment of IVIG (2 gm/kg) was given to all
eligible patients and treatment response was deter-
mined within 11 days of initial fever. As stated in the
AHA/AAP Endorsed Clinical Report, failure to re-
spond to IVIG treatment was defined as persistent fever
(temperature > 38°C) at > 36 hours from the initiation of
IVIG infusion or recurrent fever at > 36 hours after com-
pletion of the initial IVIG infusion.
We genotyped five single nucleotide polymorphisms in
the promoter region of DC-SIGN [14] using pyrosequencing
assay in a cohort of 371 KD patients; 158 White re-
sponders and 62 non-responders, 64 Asian responders
and 12 non-responders and 55 Hispanic responders and
20 non-responders recruited between 2006 and 2011.
DNA samples were extracted from either saliva or blood,
as previously described [16]. DNA amplification is
performed with one biotinylated primer to allow for purifi-
cation of a single stranded template for the pyrosequencing
reaction. Following denaturation of the PCR amplicon in
0.1 M NaOH for 10 minutes, the single stranded product is
immobilized to streptavidin-sepharose (Amersham
Biosciences), washed and annealed with 15 pmoles of a
“pyrosequencing” primer. The reaction was heated to
80C and allowed to cool to 25C. Then sequence ana-
lysis was performed by standard pyrosequencing reac-
tions using PSQHS96A pyrosequencing instrument
(Biotage, Uppsala, Sweden). The primers and probes of












ers is the minor allele as described in HapMap Whites.
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(Biotage, Uppsala, Sweden).
All analyses were performed for the entire set of KD
patients and also separately for Whites, Asians and
Hispanics, as determined by the principal component
analysis (PCA) of ancestry informative markers (AIMs), as
previously described [16]. Initially, for quality control,
Hardy-Weinberg equilibrium (HWE) for each SNP was
assessed in all KD patients and among responders and
non-responders in each ethnic group. Genotype was
available in more than 97% of the study participants and
minor allele frequency was compared with available popu-
lations in the HapMap. A case-control analytical approach
was used and chi-square test was performed to examine
the differential distribution of alleles and genotypes
between IVIG responders and non-responders. We also
performed a stratified analysis among white KD patients
(137 IVIG responders and 62 non-responders) who did
not harbor the FcγR2B polymorphisms, as previouslyTable 2 Allele and genotype distribution of five polymorphis
and non-responders in three ethnic groups
Minor allele frequency
HapMap* IVIG responders IVIG non-res






Whites (n = 158) (n = 62
rs2287886 0.31 0.35 0.36
rs4804803 0.26 0.17 0.21
rs735240 0.45 0.46 0.41
rs11465360 0.05 0.07 0.07
rs4804804 0.31 0.35 0.35
Asians (n = 64) (n = 12
rs2287886 0.71 0.57 0.79
rs4804803 0.04 0.11 0.05
rs735240 0.26 0.24 0.19
rs11465360 0.03 0.04
rs4804804 0.41 0.37 0.50
Hispanics (n = 55) (n = 20
rs2287886 0.36 0.33 0.42
rs4804803 0.14 0.08
rs735240 0.44 0.48 0.43
rs11465360 0.05 0.03
rs4804804 0.21 0.31 0.35
*For Hispanics, the frequency from the Hapmap Mexican population is shown; OR breported [16]. Further, the haplotype analyses using the 5
SNPs in the promoter region were performed in SAS/
GENETICS using the PROC HAPLOTYPE procedure.
None of the SNPs deviated from HWE, even in small
sample-size within ethnic sub-groups. Overall, the minor
frequency of all the SNPs in our participants matched
with related HapMap populations. Of the 5 known SNPs
within the DC-SIGN promoter (Table 1) [14] analyzed,
we identified an association of rs2287886 with IVIG-R in
Asian KD patients (Table 2), where the “A” allele showed
significantly lower frequency in IVIG responders, whereas
the frequency among non-responders were similar to the
HapMap Asians. Of note, “A” is the major allele in Asians,
but minor allele in Whites and Hispanics, where the asso-
ciation was not apparent. Recently, one study reported an
association of rs4804803 with KD in Asians, but not with
IVIG-R [24], consistent with our IVIG-R results However,
the low number of subjects lacking IVIG response is un-
avoidable for an uncommon disease such as low-prevalentms in the promoter of DC-SIGN among IVIG responders
Global test Additive model
ponder Allelic Genotype Odds ratio p-value
p-value p-value (OR)
)
0.51 0.48 1.11 0.53
0.73 0.94 1.00 0.73
0.36 0.09 0.92 0.37
0.98 0.98 0.91 0.96
0.56 0.61 0.90 0.58
)
0.92 0.42 1.18 0.92
0.30 0.57 1.53 0.29
0.31 0.23 0.65 0.31
0.96 0.96 0.92 0.96
0.96 0.57 0.88 0.96
)
0.04 0.08 1.76 0.05
0.28 0.57 0.68 0.29
0.32 0.56 0.71 0.31
0.72 0.71 1.14 0.71
0.23 0.13 1.37 0.23
)
0.34 0.19 2.21 0.34
0.33 0.61 0.37 0.33
0.54 0.22 0.53 0.53
0.56 0.55 0.81 0.55
0.32 0.66 0.51 0.69
ased on the additive model for minor allele.
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States, of whom 15-20% are IVIG non-responders) [25].
Polymorphisms within the promoter region of DC-SIGN
have been previously associated with disease susceptibility
for infections by pathogens and ethnic differences in allele
frequencies have also been discussed as being genetic cause
for racial differences in susceptibility to these diseases
[13,17-22]. Kawasaki Disease shows substantially higher
incidence rates in Asian populations, particularly Japanese
and these variations can also be speculated for susceptibil-
ity. Although reported rates for IVIG refractoriness are
relatively similar between Asian and cohorts of predomin-
antly white individuals [26], our prior data suggest that
genetic causes for refractoriness vary among these popula-
tions [16]. FcγR2B SNPs at -120 T/a and -386 G/c and
their minor allele haplotype are associated with positive
IVIG response in white KD patients. However, those
particular SNPs were not detected in the Asian KD patients
or their parents. In order to account for the potential
confounding effect of these variants in FcγR2B polymor-
phisms we further performed separate analyses for white
KD patients who did not harbor the variants in the two
SNPs [16]. No association with DC-SIGN polymorphisms
was noted in that specific subgroup. The frequency differ-
ences for the adverse rs2287886 DC-SIGN polymorphism
in the Asian Hapmap than in White and Hispanics is inter-
esting but should not be construed as conferring variation
in IVIG refractory rates among those populations. In fact,
ethnic specific refractory rates in U.S populations have not
been well defined. The IVIG response in the Asian and
White KD populations are both influenced by genetic
alterations, although these effects could potentially occur
at different genes within the pathway.
As noted, IgG binding to DC-SIGN purportedly stimu-
lates FcγR2B transcriptional response and receptor expres-
sion [11], but other factors including polymorphisms and
copy variation in the activating FcγR also influence IVIG
response [15,16,27]. Polymorphisms in the activating
receptor, FcγR3B, which cross links with FcγR2B, are
also associated with IVIG response in these patients,
although this effect appears consistent across ethnic/
racial populations [15]. In particular, the FcγR3B NA1
polymorphism expressed almost exclusively on neutrophils
adversely affects IVIG response. In summary, our finding
with the association of rs2287886 and IVIG response in
Asian KD patients potentially develops the hypothesis of
the involvement of DC-SIGN. While multiple comparisons
needs to be considered when testing associations with
multiple SNPs, specifically in study populations of small
sample size, the results from our study can be helpful in
deciphering the IVIG mechanism by follow-up studies
in larger KD populations or even pooling other diseases
(e.g. myocarditis, Guillain-Barré Syndrome), where IVIG
is still the choice of therapy.Ethical approval
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